7th Eurasian Hematology Oncology Summit
How I Treat Frontline CML in 2020: Does Imatinib Improve Long-Term Survival vs. Nilotinib? When Should We Adjust TKI Dose?
By
7th Eurasian Hematology Oncology Summit
FEATURING
Hagop Kantarjian
By
7th Eurasian Hematology Oncology Summit
FEATURING
Hagop Kantarjian
Comments 1
Login to view comments.
Click here to Login
